Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Sees Large Increase in Short Interest

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 27,721 shares, an increase of 169.9% from the June 30th total of 10,271 shares. Based on an average daily trading volume, of 10 shares, the short-interest ratio is currently 2,772.1 days.

Laboratorios Farmaceuticos Rovi Price Performance

Shares of Laboratorios Farmaceuticos Rovi stock remained flat at C$64.77 during trading hours on Monday. The stock has a fifty day moving average of C$65.69 and a two-hundred day moving average of C$65.80. Laboratorios Farmaceuticos Rovi has a fifty-two week low of C$65.86 and a fifty-two week high of C$65.86.

About Laboratorios Farmaceuticos Rovi

Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.